Press Room

News / Sep 23, 2019

Hovione is a Best For The World 2019 Honoree

The Best For The World lists are determined based on the verified B Impact Assessments of Certified B Corporations

Best For The World Company 2019 | Hovione

Every year, B Lab recognizes the top-performing Certified B Corporations around the world. For the second year in a row, Hovione is in the top 10% list of all B Corps that are best for Customers.

As an honoree, Hovione are a top-performing B Corp proving that competing not only to be best in the world but best for the world is a winning strategy.

Hovione has earned a place on the 2019 Best for the World list by scoring in the top 10 percent among all B Corps on the B Impact Assessment. Best for the World lists are segmented by:

  • Best Overall
  • Best for Workers
  • Best for Communities
  • Best for the Environment
  • Best for Customers
  • Best for Governance

We recall that in last June 2017 Hovione became a Certified B Corp at the B Corp Summer Summit.

Hovione was the first Chemical/Pharmaceutical Company to integrate this innovative community of companies that use the power of business to solve social an environmental problems.

 

 

 

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025